Covered recipient · General Payments record
ABEL JARELL
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$101,688.07
282 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $75,319.00 | 32 |
| Consulting Fee | $17,216.00 | 9 |
| Food and Beverage | $5,732.70 | 227 |
| Travel and Lodging | $3,413.41 | 13 |
| Education | $6.96 | 1 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AbbVie Inc. | $34,181.00 | 56 |
| GENZYME CORPORATION | $23,138.62 | 23 |
| UCB, Inc. | $14,749.57 | 32 |
| Lilly USA, LLC | $13,100.61 | 13 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $8,423.17 | 30 |
| LEO Pharma Inc. | $4,073.29 | 67 |
| Regeneron Healthcare Solutions, Inc. | $1,850.74 | 11 |
| Almirall LLC | $800.00 | 1 |
| Incyte Corporation | $367.41 | 10 |
| E.R. Squibb & Sons, L.L.C. | $204.54 | 3 |
| SANOFI-AVENTIS U.S. LLC | $162.85 | 6 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $134.67 | 6 |
| PFIZER INC. | $129.39 | 9 |
| Regeneron Pharmaceuticals, Inc. | $91.36 | 1 |
| Galderma Laboratories, L.P. | $84.86 | 4 |
| Amgen Inc. | $65.30 | 3 |
| Biofrontera Inc. | $48.68 | 3 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $37.23 | 2 |
| Genentech USA, Inc. | $23.57 | 1 |
| Janssen Scientific Affairs, LLC | $21.21 | 1 |
Page 6 of 6; records 251–282 of 282 matching records. This page contains 32 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ABEL JARELL
NPI 1275669996 · CMS profile ID 941407
Allopathic & Osteopathic Physicians / Dermatology
PORTSMOUTH, NH
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 6 of 6; records 251–282 of 282 matching records. This page contains 32 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1275669996?year=2021&recipient=provider&page=6#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ABEL JARELL, NPI 1275669996, CMS profile ID 941407. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–282 of 282 matching records. This page contains 32 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1275669996?year=2021&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). ABEL JARELL, NPI 1275669996, CMS profile ID 941407. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–282 of 282 matching records. This page contains 32 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1275669996?year=2021&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- ABEL JARELL, NPI 1275669996, CMS profile ID 941407, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 6; records 251–282 of 282 matching records. This page contains 32 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1275669996?year=2021&recipient=provider&page=6#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
282 matching records · $101,688.07 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 251–282 of 282.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| LEO Pharma Inc. | $22.07 | 02/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 842208637 | CMS |
| LEO Pharma Inc. | $11.26 | 02/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 842208647 | CMS |
| NOVARTIS PHARMACEUTICALS CORPORATION | $19.35 | 02/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815980083 | CMS |
| AbbVie Inc. | $1,300.00 | 02/19/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794953335 | CMS |
| Regeneron Healthcare Solutions, Inc. | $23.51 | 02/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809589705 | CMS |
| Regeneron Healthcare Solutions, Inc. | $21.65 | 02/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809589703 | CMS |
| UCB, Inc. | $1,600.00 | 02/17/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807299791 | CMS |
| Genentech USA, Inc. | $23.57 | 02/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835884631 | CMS |
| LEO Pharma Inc. | $22.50 | 02/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 842208629 | CMS |
| UCB, Inc. | $11.11 | 02/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807309519 | CMS |
| LEO Pharma Inc. | $21.84 | 02/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 842208621 | CMS |
| UCB, Inc. | $1,600.00 | 02/09/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807303035 | CMS |
| LEO Pharma Inc. | $103.97 | 02/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 842208609 | CMS |
| AbbVie Inc. | $6.96 | 02/06/2021 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794953329 | CMS |
| AbbVie Inc. | $13.82 | 02/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794953325 | CMS |
| AbbVie Inc. | $22.45 | 02/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794953321 | CMS |
| LEO Pharma Inc. | $18.63 | 02/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 842208601 | CMS |
| AbbVie Inc. | $1,950.00 | 02/02/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794953317 | CMS |
| LEO Pharma Inc. | $17.05 | 01/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 842208591 | CMS |
| AbbVie Inc. | $22.24 | 01/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794953313 | CMS |
| Lilly USA, LLC | $1,750.00 | 01/26/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818914875 | CMS |
| AbbVie Inc. | $11.70 | 01/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794953309 | CMS |
| UCB, Inc. | $16.67 | 01/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807295067 | CMS |
| PFIZER INC. | $19.91 | 01/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833424601 | CMS |
| Regeneron Healthcare Solutions, Inc. | $19.74 | 01/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809589701 | CMS |
| LEO Pharma Inc. | $7.31 | 01/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 842208571 | CMS |
| LEO Pharma Inc. | $23.32 | 01/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 842208580 | CMS |
| AbbVie Inc. | $1,950.00 | 01/12/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794953305 | CMS |
| UCB, Inc. | $18.40 | 01/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807292043 | CMS |
| Lilly USA, LLC | $13.15 | 01/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818903999 | CMS |
| LEO Pharma Inc. | $12.85 | 01/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 842208551 | CMS |
| LEO Pharma Inc. | $21.67 | 01/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 842208561 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,281,764.40 | 423 |
| PY2024 | Recipient | $5,272.24 | 2 |
| PY2024 | Principal investigator | $1,693,450.21 | 704 |
| PY2023 | Recipient | $14,826.00 | 1 |
| PY2023 | Principal investigator | $1,174,385.92 | 435 |
| PY2022 | Recipient | $1,189.00 | 1 |
| PY2022 | Principal investigator | $972,633.31 | 136 |
| PY2021 | Recipient | $40,692.77 | 3 |
| PY2021 | Principal investigator | $1,080,690.25 | 185 |
| PY2020 | Recipient | $1,817.37 | 4 |
| PY2020 | Principal investigator | $1,523,485.54 | 175 |
| PY2019 | Recipient | $10,937.00 | 1 |
| PY2019 | Principal investigator | $1,714,856.13 | 112 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
423 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | PFIZER INC. | $18,286.00 | 12/31/2025 | Non-covered Recipient Entity StracSkin PLLC | A PHASE 2 MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 16WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF RITLECITINIB PF06651600 IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA | No dispute reported | 06/30/2026 | 1228805888 |
| Principal investigator 1 | Arcutis Biotherapeutics, Inc. | $5,512.00 | 12/19/2025 | Non-covered Recipient Entity StracSkin PLLC | A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with AtopicDermatitis | No dispute reported | 06/30/2026 | 1248163802 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,615.00 | 12/19/2025 | Non-covered Recipient Entity STRACSKIN PLLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175427924 |
| Principal investigator 1 | Arcutis Biotherapeutics, Inc. | $1,331.20 | 12/16/2025 | Non-covered Recipient Entity StracSkin PLLC | A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with AtopicDermatitis | No dispute reported | 06/30/2026 | 1248163800 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,150.00 | 12/15/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES AND RESEARCH, INC | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1190313797 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $400.00 | 12/12/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223289686 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $80.00 | 12/12/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223289688 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $40.00 | 12/12/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223289690 |
| Principal investigator 1 | ABBVIE INC. | $1,757.40 | 12/04/2025 | Non-covered Recipient Entity STRACSKIN PLLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202527512 |
| Principal investigator 1 | ABBVIE INC. | $1,757.40 | 12/04/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202527736 |
| Principal investigator 1 | Incyte Corporation | $3,184.80 | 12/04/2025 | Non-covered Recipient Entity STRACSKIN | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240597278 |
| Principal investigator 1 | Incyte Corporation | $5,661.90 | 12/04/2025 | Non-covered Recipient Entity STRACSKIN | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240597280 |
| Principal investigator 1 | CSL Behring | $500.00 | 12/03/2025 | Non-covered Recipient Entity ALLCUTIS Research LLC | A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects | No dispute reported | 06/30/2026 | 1252670244 |
| Principal investigator 1 | CSL Behring | $2,000.00 | 12/03/2025 | Non-covered Recipient Entity ALLCUTIS Research LLC | A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects | No dispute reported | 06/30/2026 | 1252670246 |
| Principal investigator 1 | CSL Behring | $2,200.00 | 12/03/2025 | Non-covered Recipient Entity ALLCUTIS Research LLC | A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects | No dispute reported | 06/30/2026 | 1252670248 |
| Principal investigator 1 | CSL Behring | $3,000.00 | 12/03/2025 | Non-covered Recipient Entity ALLCUTIS Research LLC | A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects | No dispute reported | 06/30/2026 | 1252670250 |
| Principal investigator 1 | CSL Behring | $10,000.00 | 12/03/2025 | Non-covered Recipient Entity ALLCUTIS Research LLC | A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects | No dispute reported | 06/30/2026 | 1252670252 |
| Principal investigator 1 | CSL Behring | $2,000.00 | 12/03/2025 | Non-covered Recipient Entity ALLCUTIS Research LLC | A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects | No dispute reported | 06/30/2026 | 1252670254 |
| Principal investigator 1 | CSL Behring | $2,000.00 | 12/03/2025 | Non-covered Recipient Entity ALLCUTIS Research LLC | A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects | No dispute reported | 06/30/2026 | 1252670256 |
| Principal investigator 1 | Incyte Corporation | $40.29 | 12/01/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501203 |
| Principal investigator 1 | Incyte Corporation | $11.85 | 12/01/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501207 |
| Principal investigator 1 | Incyte Corporation | $2.37 | 12/01/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501216 |
| Principal investigator 1 | Incyte Corporation | $1.02 | 12/01/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501244 |
| Principal investigator 1 | Incyte Corporation | $47.40 | 12/01/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501248 |
| Principal investigator 1 | Incyte Corporation | $52.14 | 12/01/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501252 |
| Principal investigator 1 | Incyte Corporation | $16.59 | 12/01/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501256 |
| Principal investigator 1 | Incyte Corporation | $4.74 | 12/01/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501260 |
| Principal investigator 1 | Incyte Corporation | $4.74 | 12/01/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501264 |
| Principal investigator 1 | Incyte Corporation | $4.74 | 12/01/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501268 |
| Principal investigator 1 | Incyte Corporation | $28.44 | 12/01/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501276 |
| Principal investigator 1 | Incyte Corporation | $66.36 | 12/01/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501280 |
| Principal investigator 1 | Incyte Corporation | $23.70 | 12/01/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501284 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $7,614.60 | 12/01/2025 | Non-covered Recipient Entity STRACSKIN PLLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223289051 |
| Principal investigator 1 | Incyte Corporation | $5,499.00 | 11/25/2025 | Non-covered Recipient Entity STRACSKIN | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240597270 |
| Principal investigator 1 | Incyte Corporation | $570.00 | 11/19/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501104 |
| Principal investigator 1 | Incyte Corporation | $900.00 | 11/19/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501108 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,200.00 | 11/19/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223288521 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $100.00 | 11/19/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223288539 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $40.00 | 11/19/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223288541 |
| Principal investigator 1 | Incyte Corporation | $2,877.30 | 11/14/2025 | Non-covered Recipient Entity STRACSKIN | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240597266 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,370.00 | 11/13/2025 | Non-covered Recipient Entity STRACSKIN PLLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175427930 |
| Principal investigator 1 | Incyte Corporation | $1,532.70 | 11/07/2025 | Non-covered Recipient Entity STRACSKIN | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240597273 |
| Principal investigator 1 | ABBVIE INC. | $17,144.20 | 11/05/2025 | Non-covered Recipient Entity STRACSKIN PLLC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202522801 |
| Principal investigator 1 | ABBVIE INC. | $16,800.00 | 11/05/2025 | Non-covered Recipient Entity STRACSKIN PLLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202522803 |
| Principal investigator 1 | ABBVIE INC. | $7,060.00 | 11/05/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202522871 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $120.00 | 11/05/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223288031 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $40.00 | 11/05/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223288033 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $400.00 | 11/05/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223288035 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $120.00 | 11/05/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223288037 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $200.00 | 11/05/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223288039 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $40.00 | 11/05/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223288041 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $100.00 | 11/05/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223288043 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $40.00 | 11/05/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223288045 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $120.00 | 11/05/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223288047 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $40.00 | 11/05/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223288049 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $200.00 | 11/05/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223288051 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $120.00 | 11/05/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223288053 |
| Principal investigator 1 | ABBVIE INC. | $3,000.00 | 10/30/2025 | Non-covered Recipient Entity STRACSKIN PLLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202519731 |
| Principal investigator 1 | Incyte Corporation | $3,400.20 | 10/29/2025 | Non-covered Recipient Entity STRACSKIN | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240597258 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,300.00 | 10/29/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223287753 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $140.00 | 10/29/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223287755 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $280.00 | 10/29/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223287757 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $500.00 | 10/29/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223287763 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $60.00 | 10/29/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223287765 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $300.00 | 10/29/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223287771 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $120.00 | 10/29/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223287773 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $60.00 | 10/29/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223287775 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $100.00 | 10/29/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223287777 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $20.00 | 10/29/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223287779 |
| Principal investigator 1 | Incyte Corporation | $4,410.00 | 10/23/2025 | Non-covered Recipient Entity STRACSKIN | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240597262 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $11,611.25 | 10/22/2025 | Non-covered Recipient Entity STRACSKIN PLLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223287281 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $13,875.00 | 10/17/2025 | Non-covered Recipient Entity STRACSKIN PLLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223287083 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,000.00 | 10/17/2025 | Non-covered Recipient Entity STRACSKIN PLLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223287101 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,000.00 | 10/17/2025 | Non-covered Recipient Entity STRACSKIN PLLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223287103 |
| Principal investigator 1 | Eli Lilly and Company | $5,425.65 | 10/16/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | AN OPEN-LABEL, 24-WEEK STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS AND SKIN OF COLOR | No dispute reported | 06/30/2026 | 1187871529 |
| Principal investigator 1 | ABBVIE INC. | $4,600.00 | 10/09/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202514547 |
| Principal investigator 1 | Incyte Corporation | $2,055.60 | 10/09/2025 | Non-covered Recipient Entity STRACSKIN | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240597251 |
| Principal investigator 1 | Incyte Corporation | $3,365.00 | 10/03/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240501100 |
| Principal investigator 1 | Incyte Corporation | $1,798.00 | 10/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501112 |
| Principal investigator 1 | Incyte Corporation | $2,768.00 | 10/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501116 |
| Principal investigator 1 | Incyte Corporation | $2,768.00 | 10/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501119 |
| Principal investigator 1 | Incyte Corporation | $2,768.00 | 10/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501123 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 10/01/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501197 |
| Principal investigator 1 | Incyte Corporation | $135.40 | 10/01/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501200 |
| Principal investigator 1 | Incyte Corporation | $59.13 | 10/01/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501211 |
| Principal investigator 1 | Incyte Corporation | $68.70 | 10/01/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501220 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 10/01/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501224 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 10/01/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501228 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 10/01/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501232 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 10/01/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501236 |
| Principal investigator 1 | Incyte Corporation | $74.04 | 10/01/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501240 |
| Principal investigator 1 | Incyte Corporation | $8.48 | 10/01/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501272 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,153.00 | 09/29/2025 | Non-covered Recipient Entity STRACSKIN PLLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175427936 |
| Principal investigator 1 | Arcutis Biotherapeutics, Inc. | $2,033.20 | 09/26/2025 | Non-covered Recipient Entity StracSkin PLLC | A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with AtopicDermatitis | No dispute reported | 06/30/2026 | 1248163798 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,326.71 | 09/26/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223285961 |
| Principal investigator 1 | Incyte Corporation | $1,738.80 | 09/23/2025 | Non-covered Recipient Entity STRACSKIN | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240597237 |
| Principal investigator 1 | Incyte Corporation | $2,800.00 | 09/23/2025 | Non-covered Recipient Entity STRACSKIN | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240597241 |
| Principal investigator 1 | Incyte Corporation | $15,250.00 | 09/23/2025 | Non-covered Recipient Entity STRACSKIN | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240597244 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 09/23/2025 | Non-covered Recipient Entity STRACSKIN | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240597248 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,206.81 | 09/17/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223285624 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $103.60 | 09/05/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223285137 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $200.00 | 09/05/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223285139 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $100.00 | 09/05/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223285141 |
| Principal investigator 1 | Incyte Corporation | $1,568.70 | 09/04/2025 | Non-covered Recipient Entity STRACSKIN | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240597234 |
| Principal investigator 1 | Incyte Corporation | $57.00 | 09/03/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501051 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,302.65 | 09/03/2025 | Non-covered Recipient Entity Allcutis Research Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226116603 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $12,090.75 | 09/03/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223285061 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,300.00 | 09/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223284743 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,200.00 | 09/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223284745 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,500.00 | 09/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223284747 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $100.00 | 08/27/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223284647 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $20.00 | 08/27/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223284649 |
| Principal investigator 1 | Incyte Corporation | $4,535.10 | 08/26/2025 | Non-covered Recipient Entity STRACSKIN | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240597230 |
| Principal investigator 1 | Incyte Corporation | $1,842.00 | 08/21/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240500887 |
| Principal investigator 1 | Incyte Corporation | $1,798.00 | 08/20/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500900 |
| Principal investigator 1 | Incyte Corporation | $2,768.00 | 08/20/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500908 |
| Principal investigator 1 | Incyte Corporation | $390.00 | 08/20/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500912 |
| Principal investigator 1 | Incyte Corporation | $220.00 | 08/20/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500933 |
| Principal investigator 1 | Incyte Corporation | $370.00 | 08/20/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500946 |
| Principal investigator 1 | Incyte Corporation | $71.00 | 08/18/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501054 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,388.86 | 08/15/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223284333 |
| Principal investigator 1 | Incyte Corporation | $2,303.00 | 08/07/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240500892 |
| Principal investigator 1 | Incyte Corporation | $150.00 | 08/06/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500979 |
| Principal investigator 1 | Incyte Corporation | $140.00 | 08/06/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500982 |
| Principal investigator 1 | Incyte Corporation | $140.00 | 08/06/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500987 |
| Principal investigator 1 | Incyte Corporation | $190.00 | 08/06/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500990 |
| Principal investigator 1 | Incyte Corporation | $430.00 | 08/06/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500994 |
| Principal investigator 1 | Incyte Corporation | $10.00 | 08/06/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500998 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 08/06/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501002 |
| Principal investigator 1 | Incyte Corporation | $45.00 | 08/06/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501005 |
| Principal investigator 1 | Incyte Corporation | $40.00 | 08/06/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501009 |
| Principal investigator 1 | Incyte Corporation | $120.00 | 08/06/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501014 |
| Principal investigator 1 | Incyte Corporation | $110.00 | 08/06/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501017 |
| Principal investigator 1 | Incyte Corporation | $110.00 | 08/06/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501022 |
| Principal investigator 1 | Incyte Corporation | $40.00 | 08/06/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501039 |
| Principal investigator 1 | Incyte Corporation | $170.00 | 08/06/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501076 |
| Principal investigator 1 | Incyte Corporation | $70.00 | 08/06/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501080 |
| Principal investigator 1 | Incyte Corporation | $150.00 | 08/06/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501084 |
| Principal investigator 1 | Incyte Corporation | $40.00 | 08/06/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501088 |
| Principal investigator 1 | Incyte Corporation | $120.00 | 08/06/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501092 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $100.00 | 08/06/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223283917 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $20.00 | 08/06/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223283919 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $9,839.82 | 08/04/2025 | Non-covered Recipient Entity Allcutis Research Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226116590 |
| Principal investigator 1 | Incyte Corporation | $2,000.00 | 08/01/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501026 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 08/01/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501046 |
| Principal investigator 1 | Incyte Corporation | $1,131.00 | 08/01/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501059 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,328.60 | 08/01/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283511 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $600.00 | 08/01/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283513 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $245.00 | 08/01/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283521 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $100.00 | 08/01/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283523 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $450.00 | 08/01/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223283561 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,086.20 | 08/01/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283711 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,708.70 | 08/01/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283713 |
| Principal investigator 1 | Incyte Corporation | $71.00 | 07/28/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500904 |
| Principal investigator 1 | Incyte Corporation | $900.00 | 07/28/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500916 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $245.00 | 07/23/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223283002 |
| Principal investigator 1 | Incyte Corporation | $1,703.00 | 07/22/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240500879 |
| Principal investigator 1 | Incyte Corporation | $2,768.00 | 07/18/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500896 |
| Principal investigator 1 | Incyte Corporation | $1,949.00 | 07/18/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501030 |
| Principal investigator 1 | Incyte Corporation | $2,610.00 | 07/18/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501035 |
| Principal investigator 1 | Incyte Corporation | $2,768.00 | 07/18/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501043 |
| Principal investigator 1 | Incyte Corporation | $1,949.00 | 07/18/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501072 |
| Principal investigator 1 | Incyte Corporation | $1,842.00 | 07/17/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240500875 |
| Principal investigator 1 | Incyte Corporation | $1,932.00 | 07/10/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240500884 |
| Principal investigator 1 | Incyte Corporation | $135.00 | 07/09/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500920 |
| Principal investigator 1 | Incyte Corporation | $171.00 | 07/09/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500924 |
| Principal investigator 1 | Incyte Corporation | $1,001.00 | 07/09/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500929 |
| Principal investigator 1 | Incyte Corporation | $71.00 | 07/09/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500937 |
| Principal investigator 1 | Incyte Corporation | $868.00 | 07/09/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500942 |
| Principal investigator 1 | Incyte Corporation | $912.00 | 07/09/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500951 |
| Principal investigator 1 | Incyte Corporation | $355.00 | 07/09/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500954 |
| Principal investigator 1 | Incyte Corporation | $150.00 | 07/09/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500958 |
| Principal investigator 1 | Incyte Corporation | $541.00 | 07/09/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500962 |
| Principal investigator 1 | Incyte Corporation | $270.00 | 07/09/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500966 |
| Principal investigator 1 | Incyte Corporation | $44.00 | 07/09/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500971 |
| Principal investigator 1 | Incyte Corporation | $90.00 | 07/09/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500975 |
| Principal investigator 1 | Incyte Corporation | $846.00 | 07/09/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501064 |
| Principal investigator 1 | Incyte Corporation | $135.00 | 07/09/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501068 |
| Principal investigator 1 | Incyte Corporation | $90.00 | 07/09/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501095 |
| Principal investigator 1 | ABBVIE INC. | $2,416.80 | 07/08/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202497166 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,643.50 | 07/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223282194 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,044.64 | 07/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223282208 |
| Principal investigator 1 | Incyte Corporation | $11.45 | 07/01/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498598 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $50.00 | 07/01/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223282016 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,285.00 | 06/27/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175421955 |
| Principal investigator 1 | Incyte Corporation | $1,798.00 | 06/25/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500771 |
| Principal investigator 1 | Incyte Corporation | $1,798.00 | 06/25/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500776 |
| Principal investigator 1 | Incyte Corporation | $1,798.00 | 06/25/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500779 |
| Principal investigator 1 | Incyte Corporation | $2,768.00 | 06/25/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500792 |
| Principal investigator 1 | Incyte Corporation | $2,768.00 | 06/25/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500796 |
| Principal investigator 1 | Incyte Corporation | $2,768.00 | 06/25/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500800 |
| Principal investigator 1 | Incyte Corporation | $1,798.00 | 06/25/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500871 |
| Principal investigator 1 | Incyte Corporation | $8,062.00 | 06/24/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240500666 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $2,500.00 | 06/23/2025 | Non-covered Recipient Entity Activmed Practices And Research, Inc | Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) | No dispute reported | 06/30/2026 | 1235999383 |
| Principal investigator 1 | Incyte Corporation | $100.00 | 06/23/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500686 |
| Principal investigator 1 | Incyte Corporation | $6,281.00 | 06/19/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240500671 |
| Principal investigator 1 | Janssen Research & Development, LLC | $486.00 | 06/12/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175421942 |
| Principal investigator 1 | Eli Lilly and Company | $9,757.70 | 06/05/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187875905 |
| Principal investigator 1 | Incyte Corporation | $3,365.00 | 06/05/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240500662 |
| Principal investigator 1 | Incyte Corporation | $3,075.00 | 06/05/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240501288 |
| Principal investigator 1 | Incyte Corporation | $2,500.00 | 06/05/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240501292 |
| Principal investigator 1 | Incyte Corporation | $13,500.00 | 06/05/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240501296 |
| Principal investigator 1 | Incyte Corporation | $2,000.00 | 06/04/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240500784 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 06/04/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240500788 |
| Principal investigator 1 | Incyte Corporation | $1,131.00 | 06/04/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240500813 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 06/04/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240500820 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $30,864.40 | 06/04/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223280746 |
| Principal investigator 1 | ABBVIE INC. | $2,458.80 | 06/03/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202487417 |
| Principal investigator 1 | Incyte Corporation | $91.60 | 06/03/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498550 |
| Principal investigator 1 | Incyte Corporation | $10.30 | 06/03/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498554 |
| Principal investigator 1 | Incyte Corporation | $10.30 | 06/03/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498558 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $40.00 | 06/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223280560 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $300.00 | 06/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223280562 |
| Principal investigator 1 | Incyte Corporation | $10,258.00 | 05/28/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240500653 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,528.92 | 05/27/2025 | Non-covered Recipient Entity Allcutis Research Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226116548 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,130.00 | 05/26/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175421936 |
| Principal investigator 1 | Arcutis Biotherapeutics, Inc. | $6,500.00 | 05/23/2025 | Non-covered Recipient Entity StracSkin PLLC | A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with AtopicDermatitis | No dispute reported | 06/30/2026 | 1248163796 |
| Principal investigator 1 | Incyte Corporation | $3,138.00 | 05/22/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240500658 |
| Principal investigator 1 | Incyte Corporation | $1,798.00 | 05/21/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500721 |
| Principal investigator 1 | Incyte Corporation | $1,798.00 | 05/21/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500859 |
| Principal investigator 1 | Incyte Corporation | $1,798.00 | 05/21/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500863 |
| Principal investigator 1 | Incyte Corporation | $1,798.00 | 05/21/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500866 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $12,091.28 | 05/21/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223280072 |
| Principal investigator 1 | Incyte Corporation | $30.00 | 05/09/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500691 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $60.00 | 05/09/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223279350 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $400.00 | 05/09/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223279352 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $80.00 | 05/09/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223279354 |
| Principal investigator 1 | ABBVIE INC. | $2,647.80 | 05/07/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202484101 |
| Principal investigator 1 | ABBVIE INC. | $231.00 | 05/06/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202482295 |
| Principal investigator 1 | Eli Lilly and Company | $1.95 | 05/06/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES AND RESEARCH INC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187875687 |
| Principal investigator 1 | Eli Lilly and Company | $25,725.00 | 05/06/2025 | Non-covered Recipient Entity GRANITE STATE DERMATOLOGY | A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT IN CLINICAL PRACTICE | No dispute reported | 06/30/2026 | 1187880039 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 05/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498519 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 05/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498523 |
| Principal investigator 1 | Incyte Corporation | $16.96 | 05/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498527 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 05/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498578 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 05/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498582 |
| Principal investigator 1 | Incyte Corporation | $1,798.00 | 05/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500683 |
| Principal investigator 1 | Incyte Corporation | $2,610.00 | 05/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500713 |
| Principal investigator 1 | Incyte Corporation | $285.00 | 05/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500725 |
| Principal investigator 1 | Incyte Corporation | $1,194.27 | 05/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500734 |
| Principal investigator 1 | Incyte Corporation | $142.00 | 05/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500738 |
| Principal investigator 1 | Incyte Corporation | $141.00 | 05/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500743 |
| Principal investigator 1 | Incyte Corporation | $1,798.00 | 05/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500747 |
| Principal investigator 1 | Incyte Corporation | $150.00 | 05/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500751 |
| Principal investigator 1 | Incyte Corporation | $1,123.77 | 05/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500755 |
| Principal investigator 1 | Incyte Corporation | $1,194.27 | 05/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500760 |
| Principal investigator 1 | Incyte Corporation | $141.00 | 05/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500764 |
| Principal investigator 1 | Incyte Corporation | $141.00 | 05/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500767 |
| Principal investigator 1 | Incyte Corporation | $342.00 | 05/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500808 |
| Principal investigator 1 | Incyte Corporation | $1,637.01 | 05/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500817 |
| Principal investigator 1 | Incyte Corporation | $141.00 | 05/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500829 |
| Principal investigator 1 | Incyte Corporation | $141.00 | 05/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500833 |
| Principal investigator 1 | Incyte Corporation | $141.00 | 05/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500837 |
| Principal investigator 1 | Incyte Corporation | $141.00 | 05/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500841 |
| Principal investigator 1 | Incyte Corporation | $1,798.00 | 05/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500845 |
| Principal investigator 1 | Incyte Corporation | $1,798.00 | 05/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500849 |
| Principal investigator 1 | Incyte Corporation | $1,798.00 | 05/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500854 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $448.60 | 05/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223278880 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,038.60 | 05/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223278882 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $345.00 | 05/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223278884 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $200.00 | 05/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223278886 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,725.00 | 05/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223278888 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $327.20 | 05/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223278890 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,679.16 | 05/01/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223278784 |
| Principal investigator 1 | Incyte Corporation | $13,136.00 | 04/28/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240500640 |
| Principal investigator 1 | Incyte Corporation | $1,703.00 | 04/28/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240500644 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,808.00 | 04/28/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175421962 |
| Principal investigator 1 | Eli Lilly and Company | $69,351.00 | 04/25/2025 | Non-covered Recipient Entity GRANITE STATE DERMATOLOGY | OBSERVATION PRIORITY E SHORT - LEBRIKIZUMAB - ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187880037 |
| Principal investigator 1 | Incyte Corporation | $141.00 | 04/23/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500675 |
| Principal investigator 1 | Incyte Corporation | $75.00 | 04/18/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500679 |
| Principal investigator 1 | Incyte Corporation | $45.00 | 04/18/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500804 |
| Principal investigator 1 | Incyte Corporation | $900.00 | 04/16/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240500729 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $9,869.89 | 04/14/2025 | Non-covered Recipient Entity Allcutis Research Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226116508 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,190.95 | 04/11/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223278006 |
| Principal investigator 1 | ABBVIE INC. | $700.00 | 04/10/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202476001 |
| Principal investigator 1 | Incyte Corporation | $80.00 | 04/09/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500708 |
| Principal investigator 1 | Incyte Corporation | $20.00 | 04/09/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500716 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $63.00 | 04/09/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223277764 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,358.32 | 04/09/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223277766 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $13,300.00 | 04/07/2025 | Non-covered Recipient Entity Downtown L A Research Center Inc | ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig | No dispute reported | 06/30/2026 | 1226142054 |
| Principal investigator 1 | Incyte Corporation | $259.70 | 04/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498497 |
| Principal investigator 1 | Incyte Corporation | $31.80 | 04/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498501 |
| Principal investigator 1 | Incyte Corporation | $180.20 | 04/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498505 |
| Principal investigator 1 | Incyte Corporation | $233.20 | 04/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498510 |
| Principal investigator 1 | Incyte Corporation | $137.80 | 04/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498515 |
| Principal investigator 1 | Incyte Corporation | $339.20 | 04/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498531 |
| Principal investigator 1 | Incyte Corporation | $43.04 | 04/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498535 |
| Principal investigator 1 | Incyte Corporation | $32.28 | 04/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498538 |
| Principal investigator 1 | Incyte Corporation | $16.14 | 04/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498541 |
| Principal investigator 1 | Incyte Corporation | $137.80 | 04/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498546 |
| Principal investigator 1 | Incyte Corporation | $127.20 | 04/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498562 |
| Principal investigator 1 | Incyte Corporation | $21.52 | 04/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498566 |
| Principal investigator 1 | Incyte Corporation | $21.52 | 04/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498570 |
| Principal investigator 1 | Incyte Corporation | $318.00 | 04/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498574 |
| Principal investigator 1 | Incyte Corporation | $43.04 | 04/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498586 |
| Principal investigator 1 | Incyte Corporation | $43.04 | 04/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498590 |
| Principal investigator 1 | Incyte Corporation | $26.90 | 04/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498594 |
| Principal investigator 1 | Incyte Corporation | $2,610.00 | 04/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500695 |
| Principal investigator 1 | Incyte Corporation | $1,926.00 | 04/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500699 |
| Principal investigator 1 | Incyte Corporation | $1,926.00 | 04/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500704 |
| Principal investigator 1 | Incyte Corporation | $2,610.00 | 04/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500824 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 04/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501136 |
| Principal investigator 1 | Incyte Corporation | $68.70 | 04/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501139 |
| Principal investigator 1 | Incyte Corporation | $68.70 | 04/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501142 |
| Principal investigator 1 | Incyte Corporation | $64.72 | 04/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501147 |
| Principal investigator 1 | Incyte Corporation | $91.60 | 04/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501151 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 04/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501155 |
| Principal investigator 1 | Incyte Corporation | $34.35 | 04/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501158 |
| Principal investigator 1 | Incyte Corporation | $76.22 | 04/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501162 |
| Principal investigator 1 | Incyte Corporation | $9.27 | 04/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501165 |
| Principal investigator 1 | Incyte Corporation | $2.12 | 04/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501169 |
| Principal investigator 1 | Incyte Corporation | $51.50 | 04/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501173 |
| Principal investigator 1 | Incyte Corporation | $5.15 | 04/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501177 |
| Principal investigator 1 | Incyte Corporation | $24.68 | 04/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501181 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 04/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501186 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 04/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501190 |
| Principal investigator 1 | Incyte Corporation | $34.35 | 04/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240501194 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,397.79 | 04/02/2025 | Non-covered Recipient Entity Allcutis Research Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226116503 |
| Principal investigator 1 | Incyte Corporation | $2,865.00 | 04/01/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240500648 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,719.16 | 03/26/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223277037 |
| Principal investigator 1 | Eli Lilly and Company | $1,163.11 | 03/25/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH INC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187880519 |
| Principal investigator 1 | Incyte Corporation | $20,787.00 | 03/19/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240500506 |
| Principal investigator 1 | Eli Lilly and Company | $11,625.84 | 03/18/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | AN OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB | No dispute reported | 06/30/2026 | 1187872307 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $200.00 | 03/14/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223276715 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $40.00 | 03/14/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223276717 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $80.00 | 03/14/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223276719 |
| Principal investigator 1 | Eli Lilly and Company | $2,228.50 | 03/10/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES AND RESEARCH INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1187874201 |
| Principal investigator 1 | ABBVIE INC. | $12,337.50 | 03/07/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202461756 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,421.32 | 03/05/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223276011 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $20.00 | 03/05/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223276013 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $200.00 | 03/05/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223276015 |
| Principal investigator 1 | Incyte Corporation | $297.70 | 03/03/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498440 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 03/03/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498445 |
| Principal investigator 1 | Incyte Corporation | $10.60 | 03/03/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498449 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 03/03/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498462 |
| Principal investigator 1 | Incyte Corporation | $123.40 | 03/03/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498471 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 03/03/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498475 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 03/03/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498480 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 03/03/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498485 |
| Principal investigator 1 | Incyte Corporation | $1,798.00 | 03/03/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500514 |
| Principal investigator 1 | Incyte Corporation | $1,798.00 | 03/03/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500566 |
| Principal investigator 1 | Incyte Corporation | $1,798.00 | 03/03/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500600 |
| Principal investigator 1 | Incyte Corporation | $1,798.00 | 03/03/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500604 |
| Principal investigator 1 | Incyte Corporation | $2,610.00 | 03/03/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500620 |
| Principal investigator 1 | Incyte Corporation | $2,610.00 | 03/03/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500624 |
| Principal investigator 1 | Incyte Corporation | $1,798.00 | 03/03/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500627 |
| Principal investigator 1 | Incyte Corporation | $1,798.00 | 03/03/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500632 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,125.00 | 03/03/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175421948 |
| Principal investigator 1 | ABBVIE INC. | $4,632.92 | 02/27/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202454380 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $25,021.50 | 02/26/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223275611 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,839.59 | 02/24/2025 | Non-covered Recipient Entity Allcutis Research Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226116495 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,303.48 | 02/21/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223275445 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $13,063.72 | 02/15/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH NEDA | A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup | No dispute reported | 06/30/2026 | 1190312905 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $40.00 | 02/14/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223275317 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $400.00 | 02/14/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223275319 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $80.00 | 02/14/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223275321 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $200.00 | 02/12/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223275169 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $80.00 | 02/12/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223275171 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $40.00 | 02/12/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223275173 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $450.00 | 02/12/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223275175 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,712.00 | 02/07/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175421967 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,050.31 | 02/07/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223274979 |
| Principal investigator 1 | ABBVIE INC. | $6,529.60 | 02/06/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202447724 |
| Principal investigator 1 | ABBVIE INC. | $6,527.60 | 02/06/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202447727 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $31,776.85 | 02/05/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223274827 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $450.00 | 02/05/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223274829 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $17,172.98 | 02/04/2025 | Non-covered Recipient Entity Allcutis Research Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226116436 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,537.91 | 02/03/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223274625 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $300.00 | 02/03/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223274627 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $450.00 | 02/03/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223274629 |
| Principal investigator 1 | Incyte Corporation | $228.00 | 01/27/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500511 |
| Principal investigator 1 | Incyte Corporation | $2,610.00 | 01/27/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500554 |
| Principal investigator 1 | Incyte Corporation | $486.00 | 01/27/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500557 |
| Principal investigator 1 | Incyte Corporation | $71.00 | 01/27/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500569 |
| Principal investigator 1 | Incyte Corporation | $1,395.90 | 01/27/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500578 |
| Principal investigator 1 | Incyte Corporation | $1,926.00 | 01/27/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500583 |
| Principal investigator 1 | Incyte Corporation | $1,798.00 | 01/27/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500587 |
| Principal investigator 1 | Incyte Corporation | $1,798.00 | 01/27/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500591 |
| Principal investigator 1 | Incyte Corporation | $1,865.43 | 01/27/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500596 |
| Principal investigator 1 | Incyte Corporation | $1,926.00 | 01/27/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500635 |
| Principal investigator 1 | Incyte Corporation | $30.00 | 01/24/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500518 |
| Principal investigator 1 | Incyte Corporation | $75.00 | 01/24/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500561 |
| Principal investigator 1 | Incyte Corporation | $45.00 | 01/24/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500574 |
| Principal investigator 1 | Incyte Corporation | $80.00 | 01/24/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500608 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $40.00 | 01/24/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223274461 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $400.00 | 01/24/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223274463 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $80.00 | 01/24/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223274465 |
| Principal investigator 1 | Incyte Corporation | $2,393.00 | 01/17/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500539 |
| Principal investigator 1 | Incyte Corporation | $2,393.00 | 01/17/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500612 |
| Principal investigator 1 | Incyte Corporation | $2,393.00 | 01/17/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500616 |
| Principal investigator 1 | Incyte Corporation | $9,879.00 | 01/17/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240501132 |
| Principal investigator 1 | Incyte Corporation | $1,798.00 | 01/15/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500522 |
| Principal investigator 1 | Incyte Corporation | $1,798.00 | 01/15/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500526 |
| Principal investigator 1 | Incyte Corporation | $2,610.00 | 01/15/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500531 |
| Principal investigator 1 | Incyte Corporation | $2,610.00 | 01/15/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500535 |
| Principal investigator 1 | Incyte Corporation | $486.00 | 01/15/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500541 |
| Principal investigator 1 | Incyte Corporation | $1,926.00 | 01/15/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500546 |
| Principal investigator 1 | Incyte Corporation | $2,768.00 | 01/15/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240500550 |
| Principal investigator 1 | Eli Lilly and Company | $1,468.00 | 01/13/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES AND RESEARCH LLC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1187873545 |
| Principal investigator 1 | Eli Lilly and Company | $50,254.00 | 01/13/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187875907 |
| Principal investigator 1 | Eli Lilly and Company | $193,009.00 | 01/08/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A PHASE 2B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE ELTREKIBART IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA | No dispute reported | 06/30/2026 | 1187875931 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $9,737.66 | 01/08/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223273775 |
| Principal investigator 1 | Incyte Corporation | $3,724.00 | 01/07/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH, INC PORTSMOUTH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240501128 |
| Principal investigator 1 | ABBVIE INC. | $574.77 | 01/02/2025 | Non-covered Recipient Entity ALLCUTIS RESEARCH LLC | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202434272 |
| Principal investigator 1 | Incyte Corporation | $1.24 | 01/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498382 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 01/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498385 |
| Principal investigator 1 | Incyte Corporation | $45.80 | 01/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498389 |
| Principal investigator 1 | Incyte Corporation | $98.72 | 01/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498394 |
| Principal investigator 1 | Incyte Corporation | $160.30 | 01/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498398 |
| Principal investigator 1 | Incyte Corporation | $148.08 | 01/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498403 |
| Principal investigator 1 | Incyte Corporation | $249.08 | 01/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498407 |
| Principal investigator 1 | Incyte Corporation | $64.72 | 01/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498411 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 01/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498415 |
| Principal investigator 1 | Incyte Corporation | $249.08 | 01/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498419 |
| Principal investigator 1 | Incyte Corporation | $177.39 | 01/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498423 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 01/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498427 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 01/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498431 |
| Principal investigator 1 | Incyte Corporation | $29.16 | 01/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498436 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 01/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498453 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 01/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498458 |
| Principal investigator 1 | Incyte Corporation | $12.72 | 01/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498467 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 01/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498489 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 01/02/2025 | Non-covered Recipient Entity ACTIVMED PRACTICES RESEARCH, LLC BEVERLY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240498493 |